

TABLE II COMPARATIVE STUDY OF CURRENTLY AVAILABLE LIQUID WHOLE-CELL PERTUSSIS VACCINE BASED PENTAVALENT PRODUCTS IN INDIA

Brand Name	Manu- facturer	Composition			Clinical efficacy data					Safety data (Reactogenicity), %				WHO- PQ	World wide usage	Cost (MRP in Rs.)
		Hib conju- gate	Alum. Phos. (AIO4) per 0.5 mL	Thio- mersal	Immunogenicity data (seroprotection) (%)					Efficacy/ PMS trial	Pain (Gr 3)	Swelling (>5cm)	Fever			
					D	P	T	Hib	Hep-B							
Pentavac	Serum Institute of India	PRP-T	< or equal to 1.25 mg	Yes, (0.005 %)	100	95.3	100	100	100	No	22.4	39.1	17.5	Yes	40 million	585
Comvac-5	Bharat Biotech	PRP-T	0.3 mg	Yes (0.025 mg)	98	76	98	100	98	No	9.2 (Un)	4.4 (Un)	24 (Un)	No	-	600
Easyfive- TT	Panacea	PRP-T	0.25 mg	Yes (0.025 mg)	97.7	65-72	99	89.5	97.3	No	-	42.3 (Un)	73 (warm to touch)	Yes	55 million	600
Shan5	Shantha Biotech	PRP-T	0.625 mg	Yes (<0.050 mg)	99.4	89.9	99.4	98.3	97.8	No	36.3	2.6	5.7	Yes	24 million	
Quinvaxem	Novartis vaccines	HbOC- CRM-197	0.3 mg	No (only in traces)	99	99	100	100	98	Phase IV PMS trial*	10	4	13	Yes	>400 million doses	1645
ComBEfive	Biological Evans	PRP-T	<1.25 mg	Yes, (0.01% w/v)	98.3	96.5	100	89.5	94.7	No	13	4	28	Yes	-	580

NP-not published; D-Diphtheria; P-Pertussis; T-Tetanus; Hib-Hemophilus influenza type b; Hep-B-Hepatitis-B; PMS-Post-marketing surveillance; *PMS trial in Guatemala; Un-unspecified.